Skip to main content

Who makes Skyrizi and where is it made?

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 19, 2024.

Official answer

by Drugs.com

Skyrizi is made by AbbVie Inc., a U.S. pharmaceutical company located in North Chicago, Illinois. They have multiple manufacturing plants, including ones in North Chicago, IL, Lake County, IL, Worcester, MA and Wyandotte, MI., as well as globally. You can contact AbbVie at 1-800-222-6885 or online at Abbvie.com.

When was Skyrizi approved?

In April 2019 the U.S. Food and Drug Administration (FDA) first approved Skyrizi (risankizumab-rzaa) for the treatment of plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Skyrizi is also approved for adults to treat active psoriatic arthritis and Crohn's disease (both approved in 2022), and ulcerative colitis (approved in 2024).

Skyrizi is classified as an interleukin-23 (IL-23) inhibitor and helps to lower inflammation and improve symptoms in these autoimmune disorders.

What are Skyrizi's most common side effects?

Common side effects in plaque psoriasis and psoriatic arthritis include:

  • upper respiratory infections
  • headache
  • fatigue
  • injection site reactions
  • tinea (fungal) infections.

In Crohn's disease, common side effects include upper respiratory infections, headache, and arthralgia (joint pain) during the induction period, and arthralgia, injection site reactions, abdominal pain, anemia (low red blood cells), pyrexia (fever), back pain, arthropathy (joint disease), and urinary tract infection during long-term, maintenance treatment.

In ulcerative colitis, side effects include arthralgia (joint pain) during the induction period and arthralgia, pyrexia (fever), injection site reactions, and rash during the maintenance phase of treatment.

Learn More: Skyrizi Uses and Safety Information

This is not all the information you need to know about Skyrizi (risankizumab-rzaa) for safe and effective use and does not take the place of your healthcare provider's directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.

Related questions

References

Read next

How does Ilumya work to treat psoriasis?

Ilumya works by binding selectively to interleukin-23 (IL-23) which is a naturally occurring cytokine. IL-23 plays a key role in promoting inflammation and regulating other cytokines (such as IL-17) and inflammatory substances, such as TNF-α3-7. By blocking the effects of IL-23, Ilumya helps control the release of IL-17 and TNF-α, which reduces inflammation associated with psoriasis. It also decreases how many inflammatory cells are present within psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. Continue reading

Prednisone: What are 12 Things You Should Know?

Prednisone first came onto the market over sixty years ago and is still going strong. But did you know that this common drug used for a variety of different conditions also has some pretty serious side effects as well? Continue reading

Where should you not use triamcinolone acetonide cream?

You should not use topical corticosteroids like triamcinolone acetonide cream on your face, groin, or axillae (underarm, armpit) unless directed by your doctor. Using triamcinolone in these areas may lead to unwanted side effects like acne, prominent blood vessels, skin thinning (atrophy), changes in skin color or unwanted hair growth. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer